ABT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Abbott Laboratories is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who wants to act now rather than wait. The stock has solid defensive qualities, a reliable dividend history, and some supportive congress buying, but the current technical setup is still weak, recent Q1 results were mixed, and analyst sentiment has recently turned more cautious with multiple price target cuts. My direct view: hold off on a new full position today and wait for a clearer trend improvement before buying.
ABT is in a bearish technical phase. The MACD histogram is negative at -0.291 and still contracting, showing weak momentum. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which confirms the trend is below longer-term support. RSI_6 at 25.115 is extremely low and near oversold territory, but it is not yet a clean reversal signal. Price is 87.2, sitting just above S1 at 86.926 and below the pivot at 90.226, which suggests the stock is testing support rather than breaking out. The short-term pattern forecast is mildly positive, but not strong enough to override the broader trend weakness.
["Abbott remains a high-quality healthcare dividend stock with over 50 consecutive years of dividend increases.", "Revenue in Q1 2026 grew 7.78% YoY, showing the top line is still expanding.", "Congress trading data is net positive, with 3 purchases versus 1 sale over the last 90 days.", "Some analysts still maintain Outperform/Buy ratings and see valuation as attractive after the pullback.", "The stock is near support levels, which can appeal to long-term investors looking for a lower entry."]
["Q1 2026 net income fell 18.72% YoY and EPS fell 18.42% YoY, showing profit pressure.", "Gross margin declined to 52.42, indicating some margin compression.", "Several analysts cut price targets sharply after mixed Q1 results, including downgrades from Daiwa and multiple target reductions from major firms.", "Goldman Sachs removed Abbott from its US Conviction List.", "Technicals remain bearish, with the stock below the pivot and under a declining short-term trend."]
In Q1 2026, Abbott posted revenue of $11.164 billion, up 7.78% YoY, which is a healthy growth rate for a large-cap healthcare company. However, profitability weakened: net income fell 18.72% YoY to $1.077 billion, EPS declined 18.42% YoY to $0.62, and gross margin slipped to 52.42 from a year earlier. The latest quarter season was Q1 2026, and the key takeaway is that revenue growth remains solid while earnings quality and margins are under pressure.
Analyst sentiment has become more mixed to cautious recently. Daiwa downgraded ABT to Neutral and cut its target sharply to $92. Goldman Sachs removed Abbott from its US Conviction List. Several other firms, including Barclays, RBC, Piper Sandler, Oppenheimer, Stifel, BofA, Benchmark, and Evercore ISI, lowered price targets after Q1, though many still kept Overweight/Outperform/Buy ratings. Wall Street’s pros view: Abbott is still seen as a durable, high-quality healthcare name with long-term growth and dividend support. Wall Street’s cons view: recent organic growth disappointment, diabetes/medtech softness, and reduced confidence in near-term acceleration are weighing on sentiment.
